Technical and Toxicological Tests in Belarus Registration

1. Key takeaways

Technical tests and toxicological (biological) tests are condition-triggered items within Belarus’s preliminary technical works; the trigger conditions are the product’s mode of contact and its risk level. The two categories are distinct in concept, cannot substitute for each other, and must not be merged into a single item of biological compatibility testing. Technical tests examine whether the product performs as its specifications claim; toxicological tests examine whether contact between the product and the human body creates unacceptable biological risk. A non-contact device may therefore need technical tests but no toxicological tests, while a long-term implantable device will typically face both, with the toxicological scope driven by contact duration and tissue invasiveness. Because the list of works is closed under Resolution No. 211, the test programme for any given product is in principle determinable in advance from Resolution No. 55 — which is precisely what makes early classification of the product’s contact mode so valuable: it converts test planning from an open-ended negotiation into an enumerated, budgetable work package.

2. Legal basis

3. Expert insights

Insight 1: The two categories of tests answer two different questions. Technical tests answer whether the product conforms to its declared technical and performance specifications — accuracy, output, mechanical strength, software behaviour, whatever the product’s claims are. Toxicological (biological) tests answer whether contact between the product and the human body produces unacceptable biological risk — cytotoxicity, sensitisation, irritation and the other endpoints relevant to the contact scenario. The former looks at performance, the latter at safety. The practical consequence is that the two cannot substitute for each other in either direction: passing technical tests says nothing about biological safety, and a clean biological profile says nothing about performance. A non-contact device may therefore need technical tests but no toxicological tests, whereas the reverse never holds for contact devices. Planning documents that lump both into one testing package obscure which endpoints matter for the product and invite requests to redo work that was never addressed.

Insight 2: The trigger for toxicological testing relates to contact site and contact duration. Devices, and their accessories, that contact the body surface, mucous membranes or the internal environment generally fall within the scope requiring biological evaluation. The classification is not a formality — it determines which test endpoints apply, how many, and at what cost. Companies should therefore fix the product’s mode of contact in writing before determining the test programme: which tissues are contacted, for how long, intermittently or continuously, and whether accessories share the same contact profile. Only after that description is settled should the test items be selected. Reversing the order — picking tests first and describing contact to fit them — produces a mismatch that reviewers notice quickly, because the contact description, the risk classification and the test list must tell one coherent story across the dossier.

Insight 3: The applicable rules differ between foreign and domestic manufacturers. Publicly available industry sources indicate that the treatment of technical tests differs for foreign manufacturers relative to domestic ones — for example, formulations under which only domestic products undergo technical tests. GRZAN records this as a practical estimate drawn from industry sources: the point has not been verified against the official text, and the controlling reference remains the list in Resolution No. 55 together with written confirmation from the organising body. The operational takeaway is not to guess. Foreign manufacturers should ask, at filing preparation, which of the two test categories the expert body expects for their specific product, and should obtain that expectation in writing, because the difference — if confirmed — materially changes both the test budget and the laboratory sequencing plan.

Insight 4: The closed list makes the test programme calculable in advance. Since Resolution No. 211 prohibits expanding the list of works, a company can enumerate, before the project starts, the test items its product requires under the Resolution No. 55 list and attach a cost to each. The test programme thus becomes a priced, quotable budget rather than an expense that grows during review. This has three practical uses: fixed-fee quotations to clients or business units, laboratory slot booking (since accredited laboratories schedule weeks ahead), and procurement of reference samples or test materials whose lead times would otherwise collide with the 90-calendar-day limit. Companies that price the programme late — after review has begun — lose the lead time that early calculation provides, and typically pay rush premiums to laboratories to recover it.

4. Practical recommendations

1. Write the contact description first, then fix the test items. Produce a one-page statement of the product’s mode of contact — tissues, duration, frequency, accessories — and use it as the input to test planning.
2. Budget the two categories separately. List technical tests and toxicological tests as separate line items rather than merging them into a single testing-fee entry, so scope disputes cannot hide inside a lump sum.
3. Book accredited laboratories early. Tests must be performed in accredited laboratories, and laboratory scheduling eats into the 90-calendar-day limit; lock slots in advance to protect the master plan.
4. Verify out-of-list test demands in writing. If a test outside the list is requested, cite the closed-list principle of Resolution No. 211 and require the organising body to identify where the demand is grounded.

5. Verification checklist

• □ Statement of the product’s mode of contact prepared and test items derived from it
• □ Technical tests and toxicological tests budgeted as separate line items
• □ Slots with accredited laboratories locked in advance
• □ Grounds for any out-of-list test demand verified in writing
• □ Test programme pre-calculated against the list in Resolution No. 55

Regulatory information verified as of 2026-10-30.

On the Eurasian Economic Union market, GRZAN’s core capabilities concentrate on three points. First, distinguishing the applicable conditions and remaining time windows of the two pathways — Union-wide registration versus national registration in each member state: the national registration procedure for medical devices in Belarus has been switched wholesale by Council of Ministers Resolution No. 211 of 2026-04-28 (state register No. 6-1/55925, effective 2026-05-01), which compressed the total time limit for preliminary technical works to 90 calendar days, closed the list of such works and prohibited the organising body from expanding it, while the window for filing applications under the national procedure treats 2027-12-31 as the critical cut-off — pathway selection must therefore be decided in step with the time window. Second, authorised representative services: GRZAN can act as the manufacturer’s statutory representative in Belarus, undertaking registration filings, responses to technical queries, registration dossier amendments and post-market reporting obligations, and has synchronised its coordination mechanisms after Council of Ministers Resolution No. 378 of 2026-07-27 (effective 2026-07-30) transferred adverse-event functions to the state organisation for pharmaceutical supervision. Third, quality system and testing support: assistance in establishing a quality management system conforming to ISO 13485, and in organising technical documentation according to the target pathway — the national pathway follows the annex to Ministry of Health Resolution No. 55, while the Union pathway follows EEC Council Decision No. 46.

For business inquiries: info@grzanglobal.com